WO2015160314A1 - Mélange nutraceutique pour stimuler le système immunitaire - Google Patents

Mélange nutraceutique pour stimuler le système immunitaire Download PDF

Info

Publication number
WO2015160314A1
WO2015160314A1 PCT/TH2015/000025 TH2015000025W WO2015160314A1 WO 2015160314 A1 WO2015160314 A1 WO 2015160314A1 TH 2015000025 W TH2015000025 W TH 2015000025W WO 2015160314 A1 WO2015160314 A1 WO 2015160314A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
subject
administered
vaccine
compositions
Prior art date
Application number
PCT/TH2015/000025
Other languages
English (en)
Inventor
A. William Schwartz
Original Assignee
SCHWARTZ, I. Sandford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCHWARTZ, I. Sandford filed Critical SCHWARTZ, I. Sandford
Publication of WO2015160314A1 publication Critical patent/WO2015160314A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Definitions

  • Probiotics are microorganisms that are believed to provide some health benefits when consumed. They may be ingested by humans and animals. Prebiotics are non-digestible food ingredients that stimulate the growth and/or activity of bacteria in the digestive system in ways claimed to be beneficial to health. Many prebiotic and probiotic compounds have been studied, including the prebiotic Active Hexose Correlated Compound (AHCC) and the probiotic Bifidobacterium lactis 12 (BB12).
  • AHCC prebiotic Active Hexose Correlated Compound
  • BB12 probiotic Bifidobacterium lactis 12
  • AHCC is an alpha-glucan-rich dietary supplement extracted from the mycelia of Basidiomycota mushrooms, such as shitake (Latninula edodes). It contains a mix of oligosaccharides (comprising around 74% of AHCC, approximately 20% of which is the alpha- 1,4-glucantype), amino acids, lipids, and minerals.
  • AHCC is water soluble, water stable, and microcoated with candelilla wax to improve solubility in the intestines. AHCC is predominantly used for its purported ability to stimulate the immune system and as an adjuvant therapy to reduce the adverse side effects of chemotherapy. AHCC was developed in Japan in 1992, with several studies reporting a variety of therapeutic effects, including antioxidant and anticancer activity when combined with one or more other compounds, prevention of diabetes onset and liver injury, and improvement of immune response.
  • AHCC is made from the mycelia (vegetative portion) of various mushrooms in the general family of basidiomycete. It has been used to treat cancer with some apparent success.
  • Bifidobacterium is a type of gram-positive, non-motile anaerobic bacteria. It is an endosymbiotic inhabitant within the body, such as in the gastrointestinal tract of mammals, including humans. Bifidobacteria are one of the major genera of bacteria that make up the colon flora in mammals. Some Bifidobacterium strains are considered as important probiotics and used in the food industry.
  • Bifidobacteria may exert a range of beneficial health effects, including the regulation of intestinal microbial homeostasis, the inhibition of pathogens and harmful bacteria that colonize and/or infect the gut mucosa, the modulation of local and systemic immune responses, the repression of procarcinogenic enzymatic activities within the microbiota, the production of vitamins, and the bioconversion of a number of dietary compounds into bioactive molecules. It is believed that Bifidobacterium improve the gut mucosal barrier and lowers levels of lipopolysaccharide in the intestine.
  • the genus Bifidobacterium possesses a unique fructose-6-phosphate phosphoketolase pathway employed to ferment carbohydrates.
  • Much metabolic research on Bifidobacteria has focused on oligosaccharide metabolism as these carbohydrates are available in their otherwise nutrient-limited habitats.
  • BB12 alone or in combination with other compounds has a beneficial effect within gastrointestinal and immune functions. Specifically, it relieves constipation, improves fecal properties and microbiota, it has a positive effect against acute diarrhea and restores the intestinal microbiota after antibiotic treatments. Studies have further shown an advantage in treating colic and reducing the risk of rotavirus diarrhea in infants.
  • the present invention provides for a composition comprising a prebiotic and a probiotic bacteria that is capable of modulating the immune system.
  • the prebiotic is Active Hexose Correlated Compound (AHCC).
  • the probiotic bacteria is Bifidobacterium lactis BB12 (BB12).
  • the composition further comprises one or more pharmaceutically acceptable carriers.
  • the composition is retrained in a pharmaceutically acceptable carrier that is rapid release, immediate release, slow release, or delayed release.
  • the composition further comprises one or more prebiotics.
  • the composition further comprises one or more probiotic bacteria selected from the group consisting of: Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, Leuconostoc mesenteroides, Lactobacillus bulgaricus, Lactobacillus sasei, Lactobacillus salivarius, Pediococcus pentosaceus, Streptococcus thermophiles, Bacillus subtilis, Bacillus coagulans, Enteroccous faecium, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium infantis.
  • the present invention provides for a method of enhancing the immune system of a subject, the method comprising administering to the subject a therapeutically effective amount of a composition comprising AHCC and BB12.
  • the composition is administered in combination with another therapeutic agent.
  • the composition is administered orally, parenterally, intravenously, intradermally, intramuscularly, or subcutaneously.
  • the composition is administered with food or drink.
  • the subject is a human.
  • the subject is a veterinary subject.
  • the present invention provides for a method of enhancing the immune response to a vaccine in a subject, said method comprising administering to the subject the vaccine and a therapeutically effective amount of a composition comprising AHCC and BB12.
  • the composition is administered prior to the administration of the vaccine.
  • the composition is administered simultaneously with the vaccine.
  • the composition is administered after the administration of the vaccine.
  • the composition is administered in combination with another therapeutic agent.
  • the composition is administered orally, parenterally, intravenously, intradermally, intramuscularly, or subcutaneously.
  • the composition is administered with food or drink.
  • the subject is a human.
  • the subject is a veterinary subject.
  • the present invention provides for a method of enhancing the immune response to cancer in a subject, said method comprising administering to the subject a therapeutically effective amount of a cancer-specific antigen and a composition comprising AHCC and BB12.
  • the composition is administered in combination with another therapeutic agent.
  • the composition is administered orally, parenterally, intravenously, intradermally, intramuscularly, or subcutaneously.
  • the composition is administered with food or drink.
  • the subject is a human.
  • the subject is a veterinary subject.
  • Figure 1 depicts the results of an experiment comparing the hematocrit results between female human subjects who ingested the composition of the present invention and female human subjects who ingested a placebo. The improvement from baseline in the group that ingested the composition of the present invention was statistically significant after only 4 weeks.
  • Figure 2 depicts the results of an experiment comparing the number of CDl lc+ myeloid dendritic cells between human subjects who ingested the composition of the present invention and human subjects who ingested a placebo.
  • the group that ingested the composition of the present invention showed over 20% increase in myeloid dendritic cells at the end of 4 weeks, while no change was seen in the placebo group over the same period. This increase reached statistical significance in the group that ingested the composition at the end of 8 weeks.
  • Figure 3 depicts the results of an experiment comparing, the number of monocyte cells between human subjects who ingested the composition of the present invention and human subjects who ingested placebo. At the end of 8 weeks, a statistically significant increase of 30% was seen in the group ingesting the composition, while only a minor, insignificant change was seen in the placebo group (p ⁇ 0.0001).
  • Figure 4 depicts the results of an experiment comparing the number of CD14+CD16+ subset of monocyte cells between human subjects who ingested the composition of the present invention and human subjects who ingested placebo. A highly significant increase was seen in the group ingesting the composition for both the initial 4 week phase and for the phase following vaccine aa * ministration, while no change was seen in the placebo group.
  • Figure 5 depicts the results of an experiment comparing the level of vaccine-specific IgG 3 between human subjects who ingested the composition of the present invention and human subjects who ingested placebo. After administering the vaccine, only the group ingesting the composition showed a statistically significant increase in the serum levels of vaccine-specific IgG3.
  • the present invention relates to compositions of matter including a combination of a prebiotic compound and a probiotic compound. More particularly, the present invention relates to the combination of the prebiotic Active Hexose Correlated Compound (AHCC) and the probiotic Bifidobacterium lactis 12 (BB12).
  • AHCC prebiotic Active Hexose Correlated Compound
  • BB12 probiotic Bifidobacterium lactis 12
  • the present invention also relates to methods of treatment by administering the compositions of the invention to a subject in need thereof.
  • the present invention relates to methods of enhancing a subject's immune system by administering the compositions of the invention.
  • the present invention relates to methods of enhancing a subject's immune response to vaccination by administering the compositions of the invention.
  • an element means one element or more than one element.
  • abnormal when used in the context of organisms, tissues, cells or components thereof, refers to those organisms, tissues, cells or components thereof that differ in at least one observable or detectable characteristic (e.g., age, treatment, time of day, etc.) from those organisms, tissues, cells or components thereof that display the "normal” (expected) respective characteristic. Characteristics which are normal or expected for one cell or tissue type, might be abnormal for a different cell or tissue type.
  • antigen or "ag” .as used herein is defined as a molecule that provokes an immune response. This immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both.
  • antigens can be derived from recombinant or genomic DNA. A skilled artisan will understand that any DNA, which comprises a nucleotide sequences or a partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an "antigen" as that term is used herein.
  • an antigen need not be encoded solely by a full length nucleotide sequence of a gene. It is readily apparent that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations to elicit the desired immune response. Moreover, a skilled artisan will understand that an antigen need not be encoded by a "gene” at all. It is readily apparent that an antigen can be generated synthesized or can be derived from a biological sample. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a biological fluid.
  • APC antigen presenting cell
  • T cells includes, but is not limited to, monocytes/macrophages, B cells and dendritic cells (DCs).
  • anti-tumor effect refers to a biological effect which can be manifested by a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in the number of metastases, an increase in life expectancy, or amelioration of various physiological symptoms associated with the cancerous condition.
  • B cell as used herein is defined as a cell derived from the bone marrow and/or spleen. B cells can develop into plasma cells which produce antibodies.
  • a sample may be of any biological tissue or fluid from which biomarkers of the present invention may be detected, extracted, isolated, characterized or measured. Examples of such samples include but are not limited to blood, lymph, urine, gynecological fluids, biopsies, amniotic fluid and smears. Samples that are liquid in nature are referred to herein as "bodily fluids.” Biological samples may be obtained from a patient by a variety of techniques including, for example, by scraping or swabbing an area or by using a needle to aspirate bodily fluids. Methods for collecting various biological samples are well known in the art.
  • a sample will be a "clinical sample,” i.e., a sample derived , from a patient.
  • samples include, but are not limited to, bodily fluids which may or may not contain cells, e.g., blood (e.g., whole blood, serum or plasma), urine, saliva, tissue or fine needle biopsy samples, and archival samples with known diagnosis, treatment and/or outcome history.
  • Biological samples also include tissues, such as, frozen sections taken for histological purposes.
  • the sample also encompasses any material derived by processing a biological sample. Derived materials include, but are not limited to, cells (or their progeny) isolated from the sample, proteins or nucleic acid molecules extracted from the sample. Processing of a biological sample may involve one or more of: filtration, distillation, extraction, concentration, inactivation of interfering components, addition of reagents, and the like.
  • cancer as used herein is defined as a hyperproliferation of cells whose unique trait— loss of normal control— results in unregulated growth, lack of differentiation, local tissue invasion, and/or metastasis. Examples include but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, germ-cell tumors, and the like.
  • the term "container” includes any receptacle for holding the pharmaceutical composition.
  • the container is the packaging that contains the pharmaceutical composition.
  • the container is not the packaging that contains the pharmaceutical composition, i.e., the container is a receptacle, such as a box or vial that contains the packaged pharmaceutical composition or unpackaged pharmaceutical composition and the instructions for use of the pharmaceutical composition.
  • packaging techniques are well known in the art. It should be understood that the instructions for use of the pharmaceutical composition may be contained on the packaging containing the pharmaceutical composition, and as such the instructions form an increased functional relationship to the packaged product. However, it should be understood that the instructions may contain information pertaining to the compound's ability to perform its intended function, e.g., treating or preventing a disease in a subject.
  • a “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health continues to deteriorate.
  • a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.
  • a disease or disorder is "alleviated” if the severity or frequency of at least one sign or symptom of the disease or disorder experienced by a patient is reduced.
  • endogenous refers to any material from or produced inside an organism, cell, tissue or system.
  • exogenous refers to any material introduced from or produced outside an organism, cell, tissue or system.
  • “Instructional material,” as that term is used herein, includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of components of the invention in the kit for identifying or alleviating or treating the various diseases or disorders recited herein.
  • the instructional material may describe one or more methods of identifying or alleviating the diseases or disorders in a cell or a tissue of a subject.
  • the instructional material of the kit may, for example, be affixed to a container that contains the compositions of the invention or be shipped together with a container that contains the compositions of the invention. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient uses the instructional material and the compound cooperatively.
  • moduleating mediating a detectable increase or decrease in the level of a response in a subject compared with the level of a response in the subject in the absence of a treatment or compound, and/or compared with the level of a response in an otherwise identical but untreated subject.
  • the term encompasses perturbing and/or affecting a native signal or response thereby mediating a beneficial therapeutic response in a subject, preferably, a human.
  • the term "nutritional composition" may be a food product intended for human consumption, for example, a beverage, a drink, a bar, a snack, an ice cream, a dairy product, for example a chilled or a shelf-stable dairy product, a fermented dairy product, a drink, for example a milk-based drink, an infant formula, a growing-up milk, a confectionery product, a chocolate, a cereal product such as a breakfast cereal, a sauce, a soup, an instant drink, a frozen product intended for consumption after heating in a microwave or an oven, a ready-to-eat product, a fast food or a nutritional formula.
  • patient refers to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein.
  • the patient, subject or individual is a human.
  • patient as used herein is meant to include a human or a veterinary patient.
  • veterinary patients include both mammalian and non-mammalian veterinary patients, the latter including such veterinary patients as, for example, lizards and birds.
  • prebiotic includes any substance or combination of substances that may be utilized as a nutrient by a microorganism, may induce the growth and/or activity of a microorganism, may induce the replication of a microorganism, may be utilized as an energy source by the microorganism, and/or may be utilized by the microorganism for the production of biomolecules (i.e. R A, DNA, and proteins).
  • prebiotics include mucopolysaccharides, oligosaccharides, polysaccharides, amino acids, vitamins, nutrient precursors, harvested metabolic products of biological organisms, microbial lysates, lipids, and proteins.
  • probiotic include live microorganisms that beneficially affect the health of a host.
  • the benefits to the health of the host include, but are not limited to, improving the microbial balance of the intestines.
  • Other beneficial effects to the host include, for example, enhancing the immune system, stimulation of phagocytotic activity, stimulation of interferon, reduction of hypertension, decrease in the risk of cancer, increase in antimicrobial activity and immunomodulating effects, reduction of hypercholesterolemia, and treatment of cancer.
  • the term "pharmaceutical composition” refers to a mixture of at least one compound of the invention with other chemical components and entities, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
  • the pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.
  • “Pharmaceutically acceptable” refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
  • “Pharmaceutically acceptable carrier” refers to a medium that does not interfere with the effectiveness of the biological activity of the active ingredient(s) and is not toxic to the host to which it is administered.
  • the term "pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function.
  • a pharmaceutically acceptable material, composition or carrier such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function.
  • Such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound, useful within the invention, and not injurious to the patient.
  • materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline
  • pharmaceutically acceptable carrier also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions.
  • the "pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the invention.
  • Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference
  • T cell as used herein is defined as a thymus-derived cell that participates in a variety of cell-mediated immune reactions.
  • T-helper indicates a sub-group of lymphocytes (a type of white blood cell or leukocyte) including different cell types identifiable by a skilled person.
  • T-helper cell according to the present disclosure include effector Th cells (such as Thl, Th2 and Thl7). These Th cells secrete cytokines, proteins or peptides that stimulate or interact with other leukocytes.
  • treatment means obtaining a desired pharmacological and/or physiological effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of partially or completely curing a disease and/or adverse effect attributed to the disease.
  • treatment covers any treatment of a disease in a subject and includes: (a) preventing a disease related to an undesired immune response from occurring in a subject which may be predisposed to the disease; (b) inhibiting the disease, i.e. arresting its development: or (c) relieving the disease, i.e. causing regression of the disease.
  • terapéutica as used herein means a treatment and/or prophylaxis.
  • a therapeutic effect is obtained by suppression, remission, or eradication of a disease state.
  • Effective amount or “therapeutically effective amount” are used interchangeably herein, and refer to an amount of a compound, formulation, material, or composition, as described herein effective to achieve a particular biological result. Such results may include, but are not limited to, the inhibition of virus infection as determined by any means suitable in the art.
  • range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, 6, and any whole and partial increments therebetween. This applies regardless of the breadth of the range.
  • the present invention relates to the unexpected discovery that certain compositions comprising prebiotics and probiotic bacteria are effective in enhancing a subject's immune system and immune response.
  • the present invention relates to the unexpected discovery that the composition comprising AHCC and BB12 provides surprising results in the enhancement of a subject's immune system, such as through an increase in red blood cell count, hemoglobin content, and hematocrit.
  • the results presented herein demonstrate that the compositions of the present invention have particular benefits in augmenting a subject's immune response by improving antigen presentation and immunoglobulin secretion.
  • the present invention provides compositions and methods to enhance the immune system. Therefore the present invention includes compositions and methods to provide a therapeutic benefit by enhancing the immune system.
  • the composition of the invention comprises a combination of a prebiotic and a probiotic bacteria. In one embodiment, the composition of the present invention comprises AHCC and BB12.
  • the invention relates to generically treating diseases or disorders associated with dysfunctional immune response whereby enhancing the immune system is a desired therapy.
  • the invention includes the use of AHCC and BB12 in combination with a therapeutic agent such as an anti-tumor agent, a chemotherapeutic agent, an anti-cell proliferation agent, an anti-tumor vaccine and the like.
  • the present invention provides a generic concept for administering a prebiotic and probiotic bacteria as a therapy for enhancing a subject's immune system or immune response.
  • administering a prebiotic and probiotic bacteria enhances the immune system thereby providing an advantageous scenario for more effective vaccinations.
  • a prebiotic of the invention can be a saccharide that is difficult to digest, non-digestible or essentially non-digestible by a human and acts to encourage the growth of probiotic bacteria in the gut, increase adhesion of probiotic bacteria in the gut, displace pathogens, or provide a fermentable dose of carbohydrate to probiotic bacteria (symbiotic) or selected commensal bacteria and increase the levels of those microbial populations (notably lactobacilli and bifidobacteria) in the gastrointestinal tract.
  • a prebiotic can be a saccharide that is non- digestible by the human host and can act as a non-digestible fiber in the diet.
  • prebiotics can include one or more of a carbohydrate, carbohydrate monomer, carbohydrate oligomer, or carbohydrate polymer.
  • the prebiotic is AHCC.
  • AHCC refers to a mixture of polysaccharides, amino acids, lipids and minerals derived from cocultured mycelia of several species of Basidiomycete mushrooms. AHCC has been implicated with immunomodulation and protection against infection. AHCC can enhance tumor immune surveillance by regulating both innate and adaptive immune responses (Gao, Y. et al., Cancer Immunol. Immunother., 55(10): 1258-1266, 2006; Ritz, B.W. et al, J. Nutr. 136:2868-2873, 2006). AHCC is commercially provided by Amino Up Chemical Co. Ltd, Japan.
  • AHCC may increase macrophage antigen presentation activity and inhibition of tumor-derived immune suppressive factors, enhance macrophage proliferation and activation, promote differentiation of Thl cells; increase macrophage production of IL- 12, increase NK activity; promote apoptosis of cancer cells.
  • AHCC in cancer patients has been reported to increase TNF-a, ⁇ -interferon, interleukin-12 and decrease immunosuppressive acidic protein (LAP) and tumor growth factor (TGF)-a.
  • LAP immunosuppressive acidic protein
  • TGF tumor growth factor
  • a probiotic of the invention relates to microorganisms (e.g., bacteria, yeast, fungus and/or virus) which may form a portion of host flora, for example transient flora, and/or which may confer a therapeutic benefit to a host, for example when administered in adequate amounts.
  • microorganisms e.g., bacteria, yeast, fungus and/or virus
  • probiotic bacteria include Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, Leuconostoc mesenteroides, Lactobacillus bulgaricus, Lactobacillus sasei, Lactobacillus salivarius, Pediococcus pentosaceus, Streptococcus thermophiles, Bacillus subtilis, Bacillus coagulans, and Enteroccous faecium.
  • the probiotic bacteria is BB12.
  • BB12 refers to a particular strain of Bifidobacterium probiotic bacteria.
  • the AHCC and BB12 composition may be administered with additional probiotic bacteria.
  • the probiotic bacteria is a Bifidobacterium selected from the group consisting of Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium asteroids, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium pseudocatenulatum.
  • Bifidobacterium selected from the group consisting of Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium asteroids, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium pseudocatenulatum.
  • the probiotic bacteria of the present invention may also include mutant, variant, and genetically modified mutants of probiotic bacteria strains whose genetic and/or phenotypic properties are altered compared to the parent strain.
  • Naturally occurring variants of probiotic bacteria strains include the spontaneous alterations of targeted properties selectively isolated while deliberate alteration of parent strain properties is accomplished by conventional genetic manipulation technologies, such as gene disruption, conjugative transfer, etc.
  • probiotic bacteria The general state of probiotic bacteria is in the form of viable cells, or freeze-dried cells (which was used to generate the data herein). However, it can also be extended to nonviable cells such as killed cultures or compositions containing beneficial factors expressed by the probiotic bacteria. This could include thermally killed micro- organisms or micro-organisms killed by exposure to altered pH or subjection to pressure. With non-viable cells product preparation is simpler, cells may be incorporated easily into pharmaceuticals and storage requirements are much less limited than viable cells.
  • the present invention provides methods of treatment using the compositions of the invention.
  • the methods relate to methods of enhancing the immune system.
  • the methods relate to methods of enhancing the immune response to vaccination.
  • the method relates to enhancing the immune response to treat a disease or disorder that is associated with dysfunctional immune response.
  • the methods relate to methods of enhancing the immune response to treat cancer.
  • the methods relate to methods of enhancing the immune response to instances where the immune system is challenged or compromised, such as in therapy, surgery and the likes.
  • the methods relate to the administration of a therapeutic amount of the compositions of the invention.
  • a subject may be administered from 0.5mg to lOOg of the compositions of the invention.
  • subject may be administered from lmg to 12g of the compositions of the invention.
  • the present invention includes methods of enhancing the immune system by administering the compositions of the invention to a subject.
  • the methods include methods of potentiating an immune response in normal subjects, in subjects who are immunocompromised, or in subjects who are at risk of infection due to disease, hospitalization, age or other predisposing medical factors.
  • the methods of the present invention are effective in generally boosting the immune system in normal subjects.
  • Normal subjects have a normally functioning immune system but may wish to enhance their immune system.
  • normal subjects may use the methods of the present invention to maintain their health or as prophylaxis against possible immune system challenges.
  • the methods of the present invention are effective in boosting the immune response, for example, of subjects who are injured, immunocompromised or protein malnourished.
  • Immunocompromised subjects generally exhibit an attenuated or reduced ability to mount a normal cellular or humoral defense to challenge by infectious agents, e.g., viruses, bacteria, fungi and protozoa.
  • Protein malnourished subjects generally have a serum albumin level of less than about 3.2 grams per deciliter (g/dl) and/or unintentional weight loss of greater than 10% of usual body weight.
  • the methods of the present invention can be used to therapeutically or prophylactically treat subjects who are at a heightened risk of infection due to imminent surgery, injury, illness, radiation or chemotherapy, or other condition which deleteriously affects the immune system.
  • the method is useful to treat subjects who have a disease or disorder which causes the normal metabolic immune response to be reduced or depressed, such as HIV infection (AIDS).
  • HIV infection HIV infection
  • the method can be used to pre-initiate the metabolic immune response in subjects who are undergoing chemotherapy or radiation therapy, or who are at a heightened risk for developing secondary infections or post-operative complications because of a disease, disorder or treatment resulting in a reduced ability to mobilize the body's normal metabolic responses to infection.
  • Treatment with the compositions of the invention has been shown to be particularly effective in mobilizing the host's normal immune defenses, thereby engendering a measure of protection from infection in the treated host.
  • the present invention includes methods of enhancing a subject's immune response to vaccination by administering the compositions of the present invention, such as an adjuvant.
  • Adjuvant activity is manifested by a significant increase in immune-mediated protection by development of an immune response in an individual who otherwise would not respond at all to a vaccine.
  • Enhancement of humoral immunity is typically manifested by a significant increase in the titer of antibody raised to the antigen.
  • the methods of the present invention providing the administration of the compositions of the invention in conjunction with a vaccine, have the following advantages.
  • the total antigenic load of vaccine to be administered may be reduced since less antigen in the presence of the compositions of the invention would elicit an immunologic response at least equivalent to that achieved by the administration of the normal amount of the vaccine. Since less antigen would be required per vaccination by administering the compositions of the invention in accordance with the present invention, the probability of undesirable side-effects associated with some vaccines currently in use would be reduced.
  • compositions of the invention in conjunction with a vaccine.
  • Types of individual who should benefit from the methods of the present invention include (1) those types having impaired immune responsiveness, (2) those individuals who appear normal but who are nevertheless nonresponsive to certain vaccines as well as (3) individuals undergoing immunosuppressive therapies such as radiation and chemotherapy.
  • the vaccines contemplated for use in accordance with the present invention include but are not limited to bacterial vaccines, toxoid vaccines (inactivated toxins), and viral vaccines, or mixtures thereof used for active immunization. See for example chapter 75 entitled “Immunizing Agents” in Remington's Pharmaceutical Sciences 14th Edition 1990 Mack Publishing Co. p 1426-1441 and the antitoxins, toxoids, vaccines and live vaccines approved by the U.S. Food and Drug Administration and listed on page 208-209 (Product Category Index) of the Physician's Desk Reference, 46th Ed. 1992.
  • Suitable bacterial vaccines include bacterial vaccines against the following disease entities or states: cholera, pertussis, plague, typhoid fever, meningitis, pneumococcal pneumonia, H. influenza type B, leprosy, gonorrhea, Group B meningococcus, and Group B streptococcus, Gram-negative sepsis, E. coli sepsis, and Pseudomonas aeruginosa.
  • Suitable toxoids include diphtheria toxoid, botulism toxid, and tetanus toxoid.
  • Suitable viral vaccines include live and inactivated viral vaccines against the following disease entities or states: poliomyelitis, measles rubella, yellow fever, mumps, hepatitis B, hepatitis C and viral influenza.
  • compositions of the invention may be used to enhance the protection afforded by animal or human vaccines that are considered "weak” (i.e., provide diminished protection in terms of level, extent, and/or duration).
  • vaccines are bacterins such as Bordetella bacterin, Escherichia coli bacterins, Haemophilus bacterins, Leptospirosis vaccines, Moraxella bovis bacterin, Pasteurella bacterin and Vibrio fetus bacterin, pneumococcal vaccines and attenuated live or killed virus products or recombinant antigenic viral products such as hepatitis B, influenza A & B, bovine respiratory disease vaccine, infectious bovine rhinotracheitis, parainfluenza-3, respiratory syncytial virus, bovine virus diarrhea vaccine, equine influenza vaccine, feline leukemia vaccine, feline respiratory disease vaccine rhinotracheitiscalicipneumonitis viruses, canine parovovirus vaccine, transmissible gastroenteriti
  • the invention is applicable to treating a disease or disorder that is associated with a dysfunctional immune response.
  • the dysfunctional immune response includes autoimmune diseases.
  • An autoimmune disease is the result of an inappropriate and excessive response to a self-antigen.
  • autoimmune diseases include but are not limited to, Addision's disease, alopecia areata, ankylosing spondylitis, autoimmune hepatitis, autoimmune parotitis, Crohn's disease, diabetes (Type I), dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barr syndrome, Hashimoto's disease, hemolytic anemia, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjo
  • the invention is applicable to tumor vaccines.
  • the subject has a type of cancer which expresses a tumor-specific antigen.
  • an antigenic composition can be made which comprises a tumor-specific antigen sequence component.
  • the combination a tumor-specific antigen is administered in combination with an immunostimulatory agent (e.g., AHCC and BB12) to a patient in need thereof, resulting in an improved therapeutic outcome for the patient, evidenced by, e.g., a slowing or diminution of the growth of cancer cells or a solid tumor which expresses the tumor- specific antigen, or a reduction in the total number of cancer cells or total tumor burden.
  • the present invention provides a means to increase immunogenicity of a cell to generate an induced immune response to the tumor-associated antigen in the patient.
  • the compounds of the present invention may be used in combination with existing therapeutic agents used to treat cancer. In some instances, the compounds of the invention may be used in combination these therapeutic agents to enhance the antitumor effect of the therapeutic agent.
  • the present , invention contemplates that the immunostimulatory agent (e.g., AHCC and BB12) of the invention may be used in combination with a therapeutic agent such as an anti-tumor agent including but not limited to a chemotherapeutic agent, an anti-cell proliferation agent or any combination thereof.
  • a therapeutic agent such as an anti-tumor agent including but not limited to a chemotherapeutic agent, an anti-cell proliferation agent or any combination thereof.
  • the present invention contemplates that the immunostimulatory agent of the invention may be used in combination with a targeted anti-cancer agent, such as monoclonal antibodies, signal transduction inhibitors, gene expression modulators, and the like.
  • a targeted anti-cancer agent such as monoclonal antibodies, signal transduction inhibitors, gene expression modulators, and the like.
  • any chemotherapeutic agent can be linked to the antibodies of the invention.
  • any conventional chemotherapeutic agents of the following non-limiting exemplary classes are included in the invention: alkylating agents; nitrosoureas; antimetabolites; antitumor antibiotics; plant alkyloids; taxanes; hormonal agents; and miscellaneous agents.
  • Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells, thereby interfering with DNA replication to prevent cancer cells from reproducing. Most alkylating agents are cell cycle non-specific. In specific aspects, they stop tumor growth by cross-linking guanine bases in DNA double-helix strands.
  • Non-limiting examples include busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, mechlorethamine hydrochloride, melphalan, procarbazine, thiotepa, and uracil mustard.
  • Anti-metabolites prevent incorporation of bases into DNA during the synthesis (S) phase of the cell cycle, prohibiting normal development and division.
  • Non- limiting examples of antimetabolites include drugs such as 5-fluorouracil, 6- mercaptopurine, capecitabine, cytosine arabinoside, floxuridine, fludarabine, gemcitabine, methotrexate, and thiogua ine.
  • antitumor antibiotics that generally prevent cell division by interfering with enzymes needed for cell division or by altering the membranes that surround cells. Included in this class are the anthracyclines, such as doxorubicin, which act to prevent cell division by disrupting the structure of the DNA and terminate its function. These agents are cell cycle non-specific.
  • antitumor antibiotics include dactinomycin, daunorubicin, doxorubicin, idarubicin, mitomycin-C, and mitoxantrone.
  • Plant alkaloids inhibit or stop mitosis or inhibit enzymes that prevent cells from making proteins needed for cell growth. Frequently used plant alkaloids include vinblastine, vincristine, vindesine, and vinorelbme. However, the invention should not be construed as being limited solely to these plant alkaloids.
  • taxanes affect cell structures called microtubules that are important in cellular functions. In normal cell growth, microtubules are formed when a cell starts dividing, but once the cell stops dividing, the microtubules are disassembled or destroyed. Taxanes prohibit the microtubules from breaking down such that the cancer cells become so clogged with microtubules that they cannot grow and divide.
  • Non- limiting exemplary taxanes include paclitaxel and docetaxel.
  • Hormonal agents and hormone-like drugs are utilized for certain types of cancer, including, for example, leukemia, lymphoma, and multiple myeloma. They are often employed with other types of chemotherapy drugs to enhance their effectiveness. Sex hormones are used to alter the action or production of female or male hormones and are used to slow the growth of breast, prostate, and endometrial cancers. Inhibiting the production (aromatase inhibitors) or action (tamoxifen) of these hormones can often be used as an adjunct to therapy. Some other tumors are also hormone dependent. Tamoxifen is a non-limiting example of a hormonal agent that interferes with the activity of estrogen, which promotes the growth of breast cancer cells.
  • Miscellaneous agents include chemotherapeutics such as bleomycin, hydroxyurea, L-asparaginase, and procarbazine that are also useful in the invention.
  • An anti-cell proliferation agent can further be defined as an apoptosis- inducing agent or a cytotoxic agent.
  • the apoptosis-inducing agent may be a granzyme, a Bcl-2 family member, cytochrome C, a caspase, or a combination thereof.
  • Exemplary granzymes include granzyme A, granzyme B, granzyme C, granzyme D, granzyme E, granzyme F, granzyme G, granzyme H, granzyme I, granzyme J, granzyme , granzyme L, granzyme M, granzyme N, or a combination thereof.
  • the Bcl-2 family member is, for example, Bax, Bak, Bcl-Xs, Bad, Bid, Bik, Hrk, Bok, or a combination thereof.
  • caspase is caspase- 1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, caspase- 11, caspase- 12, caspase- 13, caspase- 14, or a combination thereof.
  • the cytotoxic agent is TNF- , gelonin, Prodigiosin, a ribosome-inhibiting protein (RIP), Pseudomonas exotoxin, Clostridium difficile Toxin B, Helicobacter pylori VacA, Yersinia enterocolitica YopT, Violacein, diethylenetriaminepentaacetic acid, irofulven, Diptheria Toxin, mitogillin, ricin, botulinum toxin, cholera toxin, saporin 6, or a combination thereof.
  • TNF- gelonin
  • Prodigiosin a ribosome-inhibiting protein
  • RIP ribosome-inhibiting protein
  • Pseudomonas exotoxin Clostridium difficile Toxin B
  • Helicobacter pylori VacA Helicobacter pylori VacA
  • Yersinia enterocolitica YopT
  • an effective amount of an immuno stimulatory agent (e.g., AHCC and BB12) of the invention and a therapeutic agent is a synergistic amount.
  • a "synergistic combination" or a “synergistic amount” of a compound of the invention and a therapeutic agent is a combination or amount that is more effective in the therapeutic or prophylactic treatment of a disease than the incremental improvement in treatment outcome that could be predicted or expected from a merely additive combination of (i) the therapeutic or prophylactic benefit of the compound of the invention when administered at that same dosage as a monotherapy and (ii) the therapeutic or prophylactic benefit of the therapeutic agent when administered at the same dosage as a monotherapy.
  • the invention includes methods of enhancing a subject's immune response to therapy.
  • the methods of the present invention relate to the administration of the compositions of the invention to a subject that is exposed to any number of relevant treatment modalities, including but not limited to treatment with agents such as natalizumab, efalizumab, antiviral agents, chemotherapy, cryotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies, cytoxin, fludaribine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and irradiation.
  • agents such as natalizumab, efalizumab, antiviral agents, chemotherapy, cryotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate,
  • compositions of the present invention are especially useful to create a condition in a subject wherein repopulation, recirculation, regeneration, and/or expansion of particular cell types is favored, especially during a defined window of time following therapy.
  • Illustrative cell types include T cells, B cells, dendritic cells, and other cells of the immune system.
  • the methods of the present invention comprise the administration of the compositions of the present invention to a subject in conjunction with (e.g., before, simultaneously or following) any number of relevant treatment modalities, including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or natalizumab treatment for MS patients or efalizumab treatment for psoriasis patients or other treatments for PML patients.
  • agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or natalizumab treatment for MS patients or efalizumab treatment for psoriasis patients or other treatments for PML patients.
  • compositions of the invention may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and F 506, antibodies, or other immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludaribine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation.
  • immunosuppressive agents such as cyclosporin, azathioprine, methotrexate, mycophenolate, and F 506, antibodies
  • immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies
  • cytoxin fludaribine
  • cyclosporin FK506, rapamycin
  • mycophenolic acid steroids
  • steroids FR901228
  • cytokines irradiation.
  • compositions of the present invention are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH.
  • chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH.
  • compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan.
  • B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan.
  • subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation.
  • subjects receive an infusion of the compositions of the present invention.
  • compositions of the present invention are administered before or following surgery.
  • the methods of the present invention are useful in pain therapy, such as therapy for chronic pain, acute pain, as well as pre-, intra-, and postoperative pain.
  • the methods of the present invention comprise the administration (i.e., pre-administration, co-administration, and/or post- administration) of other treatments and/or agents to modify (e.g., enhance) the effectiveness of the compositions of the present invention.
  • the other agents include anti-pain/anti-inflammation agents.
  • the additional anti-pain/anti-inflammation agents may include one or more agents selected from the following classes of receptor antagonists and agonists and enzyme activators and inhibitors, each class, acting through a differing molecular mechanism of action for pain and/or inflammation inhibition: (1) serotonin receptor antagonists; (2) serotonin receptor agonists; (3) histamine receptor antagonists; (4) bradykinin receptor antagonists; (5) kallikrein inhibitors; (6) tachykinin receptor antagonists, including neurokinin, and neurokinin2 receptor subtype antagonists; (7) calcitonin gene-related peptide (CGRP) receptor antagonists; (8) interleukin receptor antagonists; (9) inhibitors of enzymes active in the synthetic pathway for arachidonic acid metabolites, including (a) phospholipase inhibitors, including PLA2 isoform inhibitors and PLGy isoform inhibitors, (b) cyclooxygenase inhibitors, including non-selective cyclooxygenas
  • the administration of the composition of the invention may be for either "prophylactic” or "therapeutic" purpose.
  • the composition of the present invention is provided in advance of any symptom, although in particular embodiments the vaccine aspect of the invention is provided following the onset of one or more symptoms to prevent further symptoms from developing or to prevent present symptoms from becoming worse.
  • the prophylactic administration of composition serves to prevent or ameliorate any subsequent infection or disease.
  • the pharmaceutical composition is provided at or after the onset of a symptom of infection or disease.
  • the present invention may be provided either prior to the anticipated exposure to a disease-causing agent or disease state or after the initiation of the infection or disease.
  • an effective amount of the composition would be the amount that achieves this selected result of enhancing the immune response, and such an amount could be determined as a matter of routine by a person skilled in the art.
  • an effective amount of for treating an immune system deficiency against cancer or pathogen could be that amount necessary to cause activation of the immune system, resulting in the development of an antigen specific immune response upon exposure to antigen.
  • the term is also synonymous with "sufficient amount.”
  • compositions of the invention may be delivered into a subject.
  • the subject is a mammal.
  • the subject is a cell.
  • One mechanism for delivery is by any of the methods mentioned above which physically or chemically permeabilize the cell membrane.
  • Another embodiment of the invention for transferring the AHCC and BB12 composition into cells may involve particle bombardment. This method depends on the ability to accelerate microprojectiles carrying the short chain fatty acids to a high velocity allowing them to pierce cell membranes and enter cells without killing them.
  • Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force.
  • the microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.
  • compositions of the invention may be entrapped in a liposome.
  • Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers.
  • the compositions of the invention may be immobilized on the surface of a substrate.
  • the substrate surface may be any surface capable of having an agent/ligand bound thereto or integrated into and that is biocompatible.
  • the biocompatible surface may be biodegradable or nonbiodegradable.
  • the surface may be natural or synthetic, and a synthetic surface may be a polymer.
  • the surface may comprise collagen, purified proteins, purified peptides, polysaccharides, glycosaminoglycans, or extracellular matrix compositions.
  • a polysaccharide may include for example, cellulose, agarose, dextran, chitosan, hyaluronic acid, or alginate.
  • polymers may include polyesters, polyethers, polyanhydrides, polyalkylcyanoacryllates, polyacrylamides, polyorthoesters, polyphosphazenes, polyvinylacetates, block copolymers, polypropylene, polytetrafluorethylene (PTFE), or polyurethanes.
  • the polymer may be lactic acid or a copolymer.
  • a copolymer may comprise lactic acid and glycolic acid (PLGA).
  • Nonbiodegradable surfaces may include polymers, such as poly(dimethylsiloxane) and poly(ethylene- vinyl acetate).
  • Biocompatible surfaces include for example, glass (e.g., bioglass), collagen, metal, hydroxyapatite, aluminate, bioceramic materials, hyaluronic acid polymers, alginate, acrylic ester polymers, lactic acid polymer, glycolic acid polymer, lactic acid/glycolic acid polymer, purified proteins, purified peptides, or extracellular matrix compositions.
  • Other polymers comprising a surface may include glass, silica, silicon, hydroxyapatite, hydrogels, collagen, acrolein,, polyacrylamide, polypropylene, polystyrene, nylon, or any number of plastics or synthetic organic polymers, or the like.
  • compositions of the present invention and the pharmaceutical compositions containing said compounds may be administered orally, and thus be formulated in a form suitable for oral administration, i.e. as a solid or a liquid preparation.
  • suitable solid oral formulations include tablets, capsules, pills, granules, pellets and the like.
  • Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils and the like. If formulated in form of a capsule, the compositions of the present invention comprise, in addition to the active compound and the inert carrier or diluent, a hard gelating capsule.
  • compositions of the present invention and the pharmaceutical compositions containing said compounds may be further administered intranasally, i.e. by inhalation and thus may be formulated in a form suitable for intranasal administration, i.e. as an aerosol or a liquid preparation.
  • compositions of the present invention may also, for example, be formulated as suppositories, containing conventional suppository bases for use in human or veterinary medicine or as pessaries, for example, containing conventional pessary bases.
  • compositions of the present invention may, for example, be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and may be presented in unit dose form in ampules, pre-filled syringes, small volume infusion containers or in multi-dose containers with an added preservative.
  • the injection formulations may be suitable for intradermal, subcutaneous, intramuscular, or intravenous injection.
  • the active ingredients may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredients may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
  • compositions of the invention can be administered before, concurrently with, or after the vaccine is administered.
  • the compositions of the invention are administered separately from the vaccine, although it may be administered in combination with the vaccine.
  • the composition administered may contain an immunogen that is effective in eliciting a specific response to a given pathogen or antigen, a pharmaceutically acceptable vaccine carrier, and an immunopotentiating amount of the compositions of the invention.
  • the compositions of the invention are administered prior to the administration of the vaccine and at the same site where the vaccine is to be administered.
  • the formulations and pharmaceutical compositions contemplated by the above dosage forms can be prepared with conventional pharmaceutically acceptable excipients and additives, using conventional techniques. Other adjuvants may be administered either with the vaccine or together with the compositions of the invention.
  • compositions of the invention may be administered in conjunction with each subsequent dose of the vaccine.
  • the amount of the compositions of the invention so administered with each subsequent dose of the vaccine may be more, the same or less than the amount of the compositions of the invention administered in conjunction with the initial dose of the vaccine.
  • the amount of the compositions of the invention administered with each subsequent dose of the vaccine will depend upon the antibody response of the patient after the first dose of the vaccine.
  • the immunostimulatory agent of the invention may be co-administered with various other compounds (cytokines, chemotherapeutic and/or antiviral drugs, among many others).
  • the immunostimulatory agent of the invention may be administered an hour, a day, a week, a month, or even more, in advance of an immunogenic composition, or any permutation thereof.
  • the immunostimulatory agent may be administered an hour, a day, a week, or even more, after administration of an immunogenic composition, or any permutation thereof.
  • the frequency and administration regimen will be readily apparent to the skilled artisan and will depend upon any number of factors such as, but not limited to, the type and severity ' of the disease being treated, the age and health status of the animal, the identity of the compound or compounds being administered, the route of administration of the various immunostimulatory agent and the immunogenic composition, and the like.
  • compositions comprising one or more compositions of the present invention.
  • the formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.
  • compositions may comprise additional medicinal agents, pharmaceutical agents, carriers, buffers, adjuvants, dispersing agents, diluents, and the like depending on the intended use and application.
  • Suitable pharmaceutical carriers, excipients and/or diluents include, but are not limited to, a gum, a starch (e g. corn starch, pregeletanized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g. microcrystalline cellulose), an acrylate (e.g. polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
  • a gum e g. corn starch, pregeletanized starch
  • a sugar e.g., lactose, mannitol, sucrose, dextrose
  • a cellulosic material e.g. microcrystalline cellulose
  • an acrylate e.g. polymethylacrylate
  • Pharmaceutically acceptable carriers for liquid formulations are aqueous or non-aqueous solutions, suspensions, emulsions or oils
  • non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
  • oils are those of animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, olive oil, sunflower oil, turmeric oil, fish-liver oil, another marine oil, or a lipid from milk or eggs.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media such as phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc.
  • Compositions comprising such carriers can be formulated by well-known conventional methods.
  • Suitable carriers may comprise any material which, when combined with the biologically active compound of the invention, retains the biological activity.
  • Preparations for parenteral administration may include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non- aqueous solvents examples include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles may include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
  • Intravenous vehicles may include fluid and nutrient replenishes, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
  • compositions of the present invention might comprise proteinaceous carriers, e.g., serum albumin or immunoglobulin, preferably of human origin.
  • compositions provided herein may also be administered as controlled- release compositions, i.e. compositions in which the active ingredient is released over a period of time after administration.
  • Controlled- or sustained-release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils).
  • the composition is an immediate-release composition, i.e. a composition in which all the active ingredient is released immediately after administration.
  • compositions according to the invention and as described herein in the various embodiments may or a composition comprising said compound may be administered admixed to food, functional food, drinks, medicinal food.
  • compositions are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and other primates, mammals including commercially relevant mammals such as non-human primates, cattle, pigs, horses, sheep, cats, and dogs.
  • a pharmaceutical composition of the invention may be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses.
  • a "unit dose" is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
  • the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
  • compositions of the invention will vary, depending upon the identity, size, and condition of the subject treated and further depending upon the route by which the composition is to be administered.
  • the composition may comprise between 0.1% and 100% (w/w) active ingredient.
  • composition of the invention may further comprise one or more additional pharmaceutically active agents.
  • Controlled- or sustained-release formulations of a pharmaceutical composition of the invention may be made using conventional technology.
  • compositions of the present invention may also comprise a prebiotic component.
  • prebiotic includes substances or compounds that are fermented by the intestinal flora of the pet and hence promote the growth or development of lactic acid bacteria in the gastro-intestinal tract of the pet at the expense of pathogenic bacteria.
  • the result of this fermentation can be a release of fatty acids, in particular short-chain fatty acids in the colon. This release can have the effect of reducing the pH value in the colon.
  • Non-limiting examples of suitable prebiotics include oligosaccharides, such as inulin and its hydrolysis products commonly known as fructooligosaccharides, galacto- oligosaccarides, xylo-oligosaccharides, or oligo derivatives of starch (such as pectin, beta-glucan, and resistant starch).
  • the prebiotics may be provided in any suitable form.
  • the prebiotic may be provided in the form of plant material that contains the fiber. Suitable plant materials include asparagus, artichokes, onions, wheat or chicory, or residues of these plant materials.
  • the prebiotic fiber may be provided as an inulin extract, for example extracts from chicory are suitable.
  • Suitable inulin extracts may be obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark "Raftiline”.
  • the inulin may be provided in the form of Raftiline (g) ST which is a fine white powder, which contains about 90 to about 94% by weight of inulin, up to about 4% by weight of glucose and fructose, and about 4 to 9% by weight of sucrose.
  • the fiber may be in the form of a fructooligosaccharide such as obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark "Raftilose”.
  • the inulin may be provided in the form of Raftilose (g) P95. Otherwise, the fructooligosaccharides may be obtained by hydrolyzing inulin, by enzymatic methods, or by using micro-organisms.
  • compositions also include nutritional compositions, such as oral nutritional compositions for oral consumption and optionally for enteral adsorption, wherein the nutritional composition includes the compounds of the present invention.
  • the compositions may be a liquid oral nutritional supplement (e.g., incomplete feeding) or a complete feeding.
  • the nutritional compositions may be administered in any known form including, for example, tablets, capsules, liquids, chewables, soft gels, sachets, powders, syrups, liquid suspensions, emulsions and solutions in convenient dosage forms.
  • a nutritional formula encompasses any nutritionally complete or supplementary formulation (a nutritional supplement, for example).
  • nutritionally complete are preferably nutritional products that contain sufficient types and levels of macronutrients (protein, fats and carbohydrates) and micronutrients to be sufficient to be a sole source of nutrition for the subject to which it is being administered to. Patients can receive 100% of their nutritional requirements from such complete nutritional compositions.
  • the nutritional formula is a supplementary formulation providing supplementary nutrition.
  • a "supplementary formula” may not be nutritionally complete, but preferably contains specific nutrients that are supportive, for example in combination with physical exercise, with further of the beneficial effects of the invention, and/br which address specific or additional needs of the subject.
  • the nutritional formula may be a generally applicable nutritional formula, for example adapted to subjects of a specific age, for example a formula for children, but it may also be a formula for elderly patients, for intensive care patients, or a specially adapted formula for patients suffering from a specific disease, for example.
  • Any nutritional formula may be reconstitutable, that is, present in a substantially dried, for example powdered form, or ready-to-drink, in the form of liquid formulas, for example.
  • the invention also includes a kit comprising compounds useful within the methods of the invention and an instructional material that describes, for instance, the method of administering AHCC and BB12 as described elsewhere herein, or the method of administering prebiotics and probiotics as described elsewhere herein.
  • Formulations of a pharmaceutical composition suitable for parenteral administration comprise the active ingredient combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline.
  • a pharmaceutically acceptable carrier such as sterile water or sterile isotonic saline.
  • Such formulations may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration.
  • Injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi dose containers containing a preservative.
  • Formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained- release or biodegradable formulations. Such formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.
  • the active ingredient is provided in dry (i.e., powder or granular) form for reconstitution with a suitable vehicle (e.g., sterile pyrogen free water) prior to parenteral administration of the reconstituted composition.
  • compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution.
  • This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein.
  • Such sterile injectable formulations may be prepared using a non-toxic parenterally acceptable diluent or solvent, such as water or 1,3 butane diol, for example.
  • Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono or di-glycerides.
  • compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.
  • Example 1 Effects of a nutraceutical blend on selected immune parameters
  • a randomized, double-blinded, placebo controlled study was conducted, where 52 healthy subjects ingested either a placebo or a composition comprising AHCC (1,800 mg AHCC-FD/day) with a probiotic product BB12 (12 billion CFU/day) for 8 weeks.
  • the subjects were administered a flu vaccine.
  • the ingredients of the composition were blended, then encapsulated.
  • a color-matched placebo was made using inert coloring substances and the same excipients as used in the active product. Blood was drawn at the 0, 4, and 8 week time points.
  • Observations made during the loading phase include: an increase in the numbers of myeloid dendritic cells; and an increase in CD 14+ CD 16+ monocytes ( Figures 2 and 4). These changes may have led to more effective antigen presentation during the vaccine challenge, thus preparing the immune system for an immune challenge.
  • Observations made after the vaccine challenge include: a continued increase in CD14+ monocytes (Figure 3); a continued increase in CD14+ CD16+ monocytes (Figure 4); and a specific increase in the IgG3 subclass of vaccine-specific IgG ( Figure 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions de matière comprenant une combinaison d'un composé prébiotique et d'un composé probiotique. Plus particulièrement, la présente invention concerne la combinaison du probiotique Composé corrélé d'hexose actif (AHCC) et le prébiotique Bifidobacterium lactis 12 (BB-12). Les compositions de la présente invention permettent de stimuler le système immunitaire d'un patient. Les compositions de la présente invention permettent également de stimuler la réponse immunitaire à une vaccination chez un patient. Les compositions de la présente invention permettent également de stimuler la réponse immunitaire à un cancer chez un patient.
PCT/TH2015/000025 2014-04-16 2015-04-10 Mélange nutraceutique pour stimuler le système immunitaire WO2015160314A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980401P 2014-04-16 2014-04-16
US61/980401 2014-04-16

Publications (1)

Publication Number Publication Date
WO2015160314A1 true WO2015160314A1 (fr) 2015-10-22

Family

ID=53177346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TH2015/000025 WO2015160314A1 (fr) 2014-04-16 2015-04-10 Mélange nutraceutique pour stimuler le système immunitaire

Country Status (1)

Country Link
WO (1) WO2015160314A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016035043A1 (fr) * 2014-09-04 2016-03-10 SMITH, Jerome Shelsley Composition probiotique
WO2018209139A1 (fr) * 2017-05-12 2018-11-15 Kairos Biomedical, Inc. Mélanges nutraceutiques
WO2023036214A1 (fr) * 2021-09-10 2023-03-16 香港中文大学 Composition pour la prévention, le traitement ou le contrôle du risque de tumeurs colorectales

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol Pharmazeutische Vertr Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US7101565B2 (en) * 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101565B2 (en) * 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol Pharmazeutische Vertr Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANASTASIA N. VLASOVA ET AL: "Lactobacilli and Bifidobacteria Promote Immune Homeostasis by Modulating Innate Immune Responses to Human Rotavirus in Neonatal Gnotobiotic Pigs", PLOS ONE, vol. 8, no. 10, 2 October 2013 (2013-10-02), US, pages e76962/1 - 14, XP055200427, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0076962 *
CHOWDHURY A H ET AL: "PP043-MON EFFECT OF BIFIDUS BB536 AND ACTIVE HEXOSE CORRELATED COMPOUND ON IMMUNE FUNCTION IN HEALTHY INDIVIDUALS", CLINICAL NUTRITION, vol. 32, 30 August 2013 (2013-08-30), XP028699614, ISSN: 0261-5614, DOI: 10.1016/S0261-5614(13)60355-6 *
GARDNER ELIZABETH M; BELI ELENI; KEMPF LAWRENCE P; LIFTON DANIEL; FUJII HAJIME: "Active Hexose Correlated Compound (AHCC) improves immune cell populations after influenza vaccination of healthy subjects", THE FASEB JOURNAL, vol. 24, 1 April 2010 (2010-04-01), BETHESDA; US, pages lb327, XP055200441, ISSN: 0892-6638 *
JAYAKANTHAN KABEERDOSS ET AL: "Effect of yoghurt containing Bifidobacterium lactis Bb12Â TM on faecal excretion of secretory immunoglobulin A and human beta-defensin 2 in healthy adult volunteers", NUTRITION JOURNAL, BIOMED CENTRAL, GB, vol. 10, no. 1, 23 December 2011 (2011-12-23), pages 138, XP021093701, ISSN: 1475-2891, DOI: 10.1186/1475-2891-10-138 *
YIN Z ET AL: "Effects of active hexose correlated compound on frequency of CD4<+> and CD8<+> T cells producing interferon-gamma and/or tumor necrosis factor-alpha in healthy adults", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 71, no. 12, 1 December 2010 (2010-12-01), pages 1187 - 1190, XP027481178, ISSN: 0198-8859, [retrieved on 20100821], DOI: 10.1016/J.HUMIMM.2010.08.006 *
YUNFEI GAO ET AL: "Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 55, no. 10, 16 December 2005 (2005-12-16), pages 1258 - 1266, XP019422460, ISSN: 1432-0851 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016035043A1 (fr) * 2014-09-04 2016-03-10 SMITH, Jerome Shelsley Composition probiotique
WO2018209139A1 (fr) * 2017-05-12 2018-11-15 Kairos Biomedical, Inc. Mélanges nutraceutiques
WO2023036214A1 (fr) * 2021-09-10 2023-03-16 香港中文大学 Composition pour la prévention, le traitement ou le contrôle du risque de tumeurs colorectales

Similar Documents

Publication Publication Date Title
Doron et al. Probiotics: their role in the treatment and prevention of disease
Saxelin et al. Probiotic and other functional microbes: from markets to mechanisms
Teitelbaum et al. Nutritional impact of pre-and probiotics as protective gastrointestinal organisms
O’Hara et al. Gut microbiota: mining for therapeutic potential
EP2898889B1 (fr) Bifidobactrium pour traiter l&#39;allergie aux acariens de la poussière
WO2022218335A1 (fr) Lactobacillus reuteri, utilisation, composition, médicament et aliment associés
US7901925B2 (en) Lactobacillus delbrueckii ssp. bulgaricus strain and compositions
EP2318513B1 (fr) Nouveau bifidobacterium longum probiotique
CN114376234A (zh) 活化的双歧杆菌及其应用方法
AU2015334468A1 (en) Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
JP2016501852A (ja) 糞便微生物叢の回復のための組成物、ならびにそれらを作製および使用する方法
JP2004502633A (ja) ラクトバチルス・サリバリウス（Ｌａｃｔｏｂａｃｉｌｌｕｓｓａｌｉｖａｒｉｕｓ）の使用
Chermesh et al. Probiotics and the gastrointestinal tract: where are we in 2005?
CN113226062A (zh) 包含2’-岩藻糖基乳糖（2’fl）以改善胃肠屏障的营养组合物
Kim et al. Dietary supplementation of probiotic Bacillus polyfermenticus, Bispan strain, modulates natural killer cell and T cell subset populations and immunoglobulin G levels in human subjects
Kolida et al. Gastrointestinal microflora: probiotics
CN112805020A (zh) 抗肿瘤效果增强剂
JP5019961B2 (ja) インターロイキン１０産生促進剤
JP2021524751A (ja) 組成物及びその使用
US20220280581A1 (en) Beneficial bacteria and secretory immunoglobulin a
WO2015160314A1 (fr) Mélange nutraceutique pour stimuler le système immunitaire
JP2018532380A (ja) 腸内細菌の酪酸桿菌（Ｂｕｔｙｒｉｂａｃｔｅｒ ｉｎｔｅｓｔｉｎｉ）およびその使用
Gionchetti et al. VSL# 3: an analysis of basic and clinical contributions in probiotic therapeutics
CN115414390A (zh) 具有改善肠道微生态性能和增强肿瘤免疫检查点抑制剂治疗效果的益生菌复合制剂及应用
US20200197513A1 (en) Nutraceutical blends

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15722364

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 08/02/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15722364

Country of ref document: EP

Kind code of ref document: A1